Immunotherapy in gastrointestinal cancer: The current scenario and future perspectives.
Adoptive cell therapy
Biliary
Checkpoint inhibition
Colorectal
Gastric
Gastrointestinal cancer
Hepatic
Immunotherapy
Oesophageal
Pancreatic
Review
Vaccine
Journal
Cancer treatment reviews
ISSN: 1532-1967
Titre abrégé: Cancer Treat Rev
Pays: Netherlands
ID NLM: 7502030
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
29
03
2020
revised:
07
05
2020
accepted:
09
05
2020
pubmed:
9
6
2020
medline:
30
7
2020
entrez:
8
6
2020
Statut:
ppublish
Résumé
Gastrointestinal cancers include colorectal, gastric, oesophageal, pancreatic and liver cancers. They continue to be a significant cause of mortality and morbidity worldwide. Current treatment strategies include chemotherapy, surgery, radiotherapy and targeted therapies. Immunotherapy has recently been incorporated in treatment regimens for some gastrointestinal malignancies and research into different immune modifying treatments is being carried out in this context. Approaches to immune modulation such as vaccination, adoptive cell therapy and checkpoint inhibition have shown varying clinical benefit, with most of the benefit seen in checkpoint inhibition. This review summarises recent advances and future direction of immunotherapy in patients with gastrointestinal malignancies.
Identifiants
pubmed: 32505807
pii: S0305-7372(20)30068-2
doi: 10.1016/j.ctrv.2020.102030
pii:
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Cancer Vaccines
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
102030Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declared that there is no conflict of interest.